GSK to Acquire Aiolos Bio

GSK to Acquire BELLUS Health for $2.0 Billion

April 18, 2023

Biotechnology

GSK plc entered into an agreement to acquire BELLUS Health Inc. in a cash deal valued at approximately US$2.0 billion (US$14.75 per share). The acquisition is intended to give GSK access to camlipixant, a late-stage (phase III) highly selective P2X3 antagonist for refractory chronic cough, with anticipated regulatory approval and launch in 2026 and expected EPS accretion from 2027.

GSK Acquires Elsie Biotechnologies for up to $50M

June 6, 2024

Biotechnology

GSK plc has completed the acquisition of Elsie Biotechnologies, a San Diego–based oligonucleotide-focused biotechnology company, for up to $50 million. The deal integrates Elsie's discovery, synthesis and delivery capabilities into GSK's oligonucleotide R&D platform to accelerate development of therapeutics for chronic hepatitis B, steatotic liver disease and other difficult-to-treat diseases.

GSK to Acquire IDRx in Up-to $1.15 Billion Deal

January 15, 2025

Biotechnology

GSK has entered into an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision therapeutics for GIST. The deal includes an upfront payment of $1 billion plus a potential additional $150 million success-based regulatory milestone payment.

GSK to Acquire Sierra Oncology for $1.9 Billion

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has entered into an agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. for $1.9 billion (approximately $55 per share in cash). The acquisition is intended to bring Sierra’s lead asset momelotinib—an investigational targeted therapy for myelofibrosis and anemia—into GSK’s specialty medicines portfolio.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.